FindTrial
Sign In

An Open Label, Phase 1 Study evaluating pharmacokinetics, safety and tolerability of ABT-869 in Subjects with Solid tumors

An Open Label, Phase 1 Study evaluating pharmacokinetics, safety and tolerability of ABT-869 in Subjects with Solid tumors

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220594
Enrollment
Unknown
Registered
2008-08-22
Start date
2008-08-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumors

Interventions

investigational material(s) Generic name etc : ABT-869 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Sponsors

Abbott Japan Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects aged from 20 to 75 years at date of consent. 2. Subject must have a solid tumor that is refractory to standard therapies or for which a standard effective therapy does not exist.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
pharmacokinetics, safety and tolerability—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026